Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
BUSINESS
Hisamitsu One Step Closer to FY2019 Filing after NSAID Patch Delivers Positive PIII in Cancer Pain
Hisamitsu Pharmaceutical has delivered encouraging results from its re-designed Japan PIII trial on its investigational cancer pain drug HP-3150, setting the table for its planned filing within this fiscal year ending February 2020. The study looked into the efficacy and…
To read the full story
Related Article
- Hisamitsu Applies for Diclofenac Patch for Cancer Pain in Japan
February 28, 2020
- Hisamitsu Begins New Japan PIII for NSAIDs Patch after Unfavorable PII/III
July 20, 2017
- Hisamitsu’s NSAIDs Patch Disappoints in Japan PII/III
August 30, 2016
BUSINESS
- Renalys Aims to File Sparsentan for IgA Nephropathy in Japan in 2026
April 19, 2024
- Fujifilm Shoots for 700 Billion Yen in Bio-CDMO Sales by FY2030
April 18, 2024
- Voydeya, High-Dose Eylea, Vyvdura and More Now Available in Japan
April 18, 2024
- Kyowa Pharma Reveals Fudged Accelerated Stability Test of Mestinon
April 17, 2024
- Santen’s New China Plant Completed, Poised for 2027 Launch
April 17, 2024
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Generic manufacturers in Japan will be required to disclose supply-related information from this June under a new company indicator rule…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…